These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 31722893)

  • 1. "Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis." Bridget F. Collins and Ganesh Raghu.
    Eur Respir Rev; 2019 Dec; 28(154):. PubMed ID: 31722893
    [No Abstract]   [Full Text] [Related]  

  • 2. "The therapy of idiopathic pulmonary fibrosis: what is next?" Vivien Somogyi, Nazia Chaudhuri, Sebastiano Emanuele Torrisi,
    Eur Respir Rev; 2019 Sep; 28(153):. PubMed ID: 31554706
    [No Abstract]   [Full Text] [Related]  

  • 3. "Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis." Vincent Cottin and Toby Maher. Eur Respir Rev 2015; 24: 58-64.
    Eur Respir Rev; 2015 Sep; 24(137):545. PubMed ID: 26324819
    [No Abstract]   [Full Text] [Related]  

  • 4. Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients.
    Feng H; Zhao Y; Li Z; Kang J
    Ther Adv Respir Dis; 2020; 14():1753466620963015. PubMed ID: 33070705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. "Recent lessons learned in the management of acute exacerbation of idiopathic pulmonary fibrosis." Yasuhiro Kondoh, Vincent Cottin and Kevin K. Brown.
    Eur Respir Rev; 2018 Jun; 27(148):. PubMed ID: 29653947
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis.
    Finnerty JP; Ponnuswamy A; Dutta P; Abdelaziz A; Kamil H
    BMC Pulm Med; 2021 Dec; 21(1):411. PubMed ID: 34895203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antifibrotic therapy and its indications for interstitial pulmonary fibrosis.
    Doubková M
    Vnitr Lek; 2022; 68(4):212-215. PubMed ID: 36220417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. "Immune mechanisms in fibrotic pulmonary sarcoidosis". P. Weeratunga, D.R. Moller and L-P. Ho.
    Eur Respir Rev; 2023 Sep; 32(169):. PubMed ID: 37611949
    [No Abstract]   [Full Text] [Related]  

  • 9. Novel insights in fibrotic pulmonary sarcoidosis.
    Comes A; Sofia C; Richeldi L
    Curr Opin Pulm Med; 2022 Sep; 28(5):478-484. PubMed ID: 35838359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Digital quantification of p16-positive foci in fibrotic interstitial lung disease is associated with a phenotype of idiopathic pulmonary fibrosis with reduced survival.
    Keow J; Cecchini MJ; Jayawardena N; Zompatori M; Joseph MG; Mura M
    Respir Res; 2022 Jun; 23(1):147. PubMed ID: 35672770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis.
    Collins BF; Raghu G
    Eur Respir Rev; 2019 Sep; 28(153):. PubMed ID: 31578210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. "Intersections of lung progenitor cells, lung disease and lung cancer." Carla F. Kim.
    Eur Respir Rev; 2017 Dec; 26(146):. PubMed ID: 29070583
    [No Abstract]   [Full Text] [Related]  

  • 13. Danger-associated molecular patterns and danger signals in idiopathic pulmonary fibrosis.
    Ellson CD; Dunmore R; Hogaboam CM; Sleeman MA; Murray LA
    Am J Respir Cell Mol Biol; 2014 Aug; 51(2):163-8. PubMed ID: 24749648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antifibrotic Therapies and Progressive Fibrosing Interstitial Lung Disease (PF-ILD): Building on INBUILD.
    Shumar JN; Chandel A; King CS
    J Clin Med; 2021 May; 10(11):. PubMed ID: 34070297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. "Idiopathic inflammatory myopathies and the lung." Jean-Christophe Lega, Quitterie Reynaud, Alexandre Belot, Nicole Fabien, Isabelle Durieu and Vincent Cottin. Eur Respir Rev 2015; 24: 216-238.
    Eur Respir Rev; 2015 Sep; 24(137):545. PubMed ID: 26324818
    [No Abstract]   [Full Text] [Related]  

  • 16. Erratum: "Clinical experience with antifibrotics in fibrotic hypersensitivity pneumonitis: a 3-year real-life observational study" Vasilios Tzilas, Argyris Tzouvelekis, Evangelos Bouros, Theodoros Karampitsakos, Maria Ntassiou, Eleni Avdoula, Athena Trachalaki, Katerina Antoniou, Ganesh Raghu and Demosthenes Bouros.
    ERJ Open Res; 2021 Jan; 7(1):. PubMed ID: 33681345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. "Phosphodiesterase 4B inhibition: a potential novel strategy for treating pulmonary fibrosis." M. Kolb, B. Crestani and T.M. Maher.
    Eur Respir Rev; 2024 Jan; 33(171):. PubMed ID: 38537950
    [No Abstract]   [Full Text] [Related]  

  • 18. Impact of novel antifibrotic therapy on patient outcomes in idiopathic pulmonary fibrosis: patient selection and perspectives.
    Graney BA; Lee JS
    Patient Relat Outcome Meas; 2018; 9():321-328. PubMed ID: 30288134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of antifibrotic therapy on lung cancer development in idiopathic pulmonary fibrosis.
    Naoi H; Suzuki Y; Mori K; Aono Y; Kono M; Hasegawa H; Yokomura K; Inoue Y; Hozumi H; Karayama M; Furuhashi K; Enomoto N; Fujisawa T; Nakamura Y; Inui N; Nakamura H; Suda T
    Thorax; 2022 Jul; 77(7):727-730. PubMed ID: 35354649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apoptotic PET Imaging of Rat Pulmonary Fibrosis with Small-Molecule Radiotracer.
    Xiong Y; Nie D; Liu S; Ma H; Su S; Sun A; Zhao J; Zhang Z; Xiang X; Tang G
    Mol Imaging Biol; 2019 Jun; 21(3):491-499. PubMed ID: 30167994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.